- Home
- AMWL vs AGEN Comparison
AMWL vs AGEN Comparison
Compare AMWL & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMWL
- AGEN
- Stock Information
- Founded
- AMWL 2006
- AGEN 1994
- Country
- AMWL United States
- AGEN United States
- Employees
- AMWL N/A
- AGEN N/A
- Industry
- AMWL Retail: Computer Software & Peripheral Equipment
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AMWL Technology
- AGEN Health Care
- Exchange
- AMWL Nasdaq
- AGEN Nasdaq
- Market Cap
- AMWL 111.4M
- AGEN 126.8M
- IPO Year
- AMWL 2020
- AGEN 2000
- Fundamental
- Price
- AMWL $4.00
- AGEN $4.37
- Analyst Decision
- AMWL Hold
- AGEN Buy
- Analyst Count
- AMWL 7
- AGEN 2
- Target Price
- AMWL $8.33
- AGEN $14.50
- AVG Volume (30 Days)
- AMWL 118.9K
- AGEN 518.3K
- Earning Date
- AMWL 11-04-2025
- AGEN 11-10-2025
- Dividend Yield
- AMWL N/A
- AGEN N/A
- EPS Growth
- AMWL N/A
- AGEN N/A
- EPS
- AMWL N/A
- AGEN N/A
- Revenue
- AMWL $265,023,000.00
- AGEN $106,829,000.00
- Revenue This Year
- AMWL N/A
- AGEN $60.49
- Revenue Next Year
- AMWL $3.10
- AGEN N/A
- P/E Ratio
- AMWL N/A
- AGEN N/A
- Revenue Growth
- AMWL 4.33
- AGEN N/A
- 52 Week Low
- AMWL $3.83
- AGEN $1.38
- 52 Week High
- AMWL $12.95
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- AMWL 24.25
- AGEN 55.93
- Support Level
- AMWL $3.87
- AGEN $3.63
- Resistance Level
- AMWL $4.17
- AGEN $4.67
- Average True Range (ATR)
- AMWL 0.27
- AGEN 0.26
- MACD
- AMWL -0.07
- AGEN 0.07
- Stochastic Oscillator
- AMWL 10.44
- AGEN 66.04
About AMWL American Well Corporation
American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).